1997
DOI: 10.1046/j.1365-2141.1997.1212937.x
|View full text |Cite
|
Sign up to set email alerts
|

Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF

Abstract: Summary.The most important physiological regulator of megakaryocytopoiesis is the ligand for the c-mpl receptor (thrombopoietin/megakaryocyte growth and development factor, MGDF). We examined the effect of pegylatedrecombinant human MGDF (PEG-rHuMGDF): patients received PEG-rHuMGDF at doses of 0·03, 0·1, 0·3 or 1·0 mg/kg/d or placebo for 10 d maximum in a doubleblinded randomized study. There was a dose-dependent elevation in circulating platelet counts but no alteration in erythrocyte or total leucocyte count… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
41
0

Year Published

1999
1999
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(43 citation statements)
references
References 35 publications
2
41
0
Order By: Relevance
“…Filgrastim (recombinant G-CSF) and sargramostim (recombinant GM-CSF) are approved for CD34 + cell mobilization. 1,2,4,16 Other cytokines in combination with filgrastim have been studied for potential enhancement of mobilization, including recombinant human stem cell factor (SCF, ancestim); 15,[17][18][19][20][21] recombinant human Mpl ligands; 22,23 flt-3 ligand; 24 and interleukin-3 receptor ligands. 25 SCF is an early-acting hematopoietic factor which displays pronounced synergies with other, later-acting hematopoietic factors, both in vitro and in vivo, to promote growth and maturation of primitive progenitors.…”
mentioning
confidence: 99%
“…Filgrastim (recombinant G-CSF) and sargramostim (recombinant GM-CSF) are approved for CD34 + cell mobilization. 1,2,4,16 Other cytokines in combination with filgrastim have been studied for potential enhancement of mobilization, including recombinant human stem cell factor (SCF, ancestim); 15,[17][18][19][20][21] recombinant human Mpl ligands; 22,23 flt-3 ligand; 24 and interleukin-3 receptor ligands. 25 SCF is an early-acting hematopoietic factor which displays pronounced synergies with other, later-acting hematopoietic factors, both in vitro and in vivo, to promote growth and maturation of primitive progenitors.…”
mentioning
confidence: 99%
“…Decreasing percentage changes in TPO during successive cycles of induction chemotherapy may signal a decline in the Mk reserve and the need for alternative transplant strategies. These include early PBPC harvesting, mobilization of PBPCs with r-ML alone or in combination with other cytokines, [42][43][44] and ex vivo expansion of Mk progenitors. 18 …”
Section: Discussionmentioning
confidence: 99%
“…In mice, dogs, and primates, rHuTPO and PEG-rHuMGDF promote platelet production and reduce chemotherapyinduced thrombocytopenia [7][8][9][10][11][12][13][14]. In humans, rHuTPO and PEG-rHuMGDF promote platelet production and reduce chemotherapy-induced thrombocytopenia [15][16][17][18][19]. Unfortunately, evidence of TPO-neutralizing antibodies in patients participating in cancer and in platelet donor clinical trials forced the discontinuation of PEG-rHuMGDF development [20].…”
Section: Introductionmentioning
confidence: 99%